Science and Technology

Reaches the market first specific treatment for scorpion sting

More severe cases occur most frequently in infants and children, if untreated, the bite can be fatal

Foto: FDA
Análise clínica e liberação do Anascorp foram feitas pela Food and Drug Administration
Análise clínica e liberação do Anascorp foram feitas pela Food and Drug Administration

The Food and Drug Administration (FDA) approved the first specific treatment for bites of scorpions in the United States.

More serious cases involving bites occur most frequently in infants and children and can cause shortness of breath, fluid in the lungs, shortness of breath, excess saliva, blurred vision, speech problems, difficulty swallowing, abnormal eye movements, muscle spasms , difficulty walking, and other uncoordinated muscle movements. If the patient is not treated, the accident can be fatal.

"This product offers a new treatment for adults and children and is designed specifically for scorpion sting," said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research.

Anascorp The drug is made from the plasma of horses immunized with scorpion venom. Therefore, it can cause allergic reactions in people sensitive to horse proteins. The manufacturing process includes steps to reduce the chances of allergic reactions and reduce the risk of transmitting viruses that may be present in plasma.

The effectiveness of Anascorp was based on the results of a randomized, placebo-controlled trial involving 15 children with neurological signs of scorpion stings. These signs were resolved within four hours of treatment in eight subjects who received Anascorp, but in only one of the seven participants who received placebo. The most common side effects were vomiting, fever, rash, nausea, itching, headache, runny nose and muscle aches.